---
title: Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis
nct_id: NCT02247622
overall_status: UNKNOWN
sponsor: Meir Medical Center
study_type: OBSERVATIONAL
primary_condition: Primary Sclerosing Cholangitis
countries: Israel
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02247622.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02247622"
ct_last_update_post_date: 2014-09-25
last_seen_at: "2026-05-12T06:23:41.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis

**Official Title:** Primary Sclerosing Cholangitis Telomere Length

**NCT ID:** [NCT02247622](https://clinicaltrials.gov/study/NCT02247622)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Meir Medical Center
- **Conditions:** Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
- **Start Date:** 2012-02
- **Completion Date:** 2014-09
- **CT.gov Last Update:** 2014-09-25

## Brief Summary

PSC is a chronic cholestatic disorder. The investigators intend to study some telomere parameters and telomere length in order to predict a premalignant state.

## Detailed Description

Primary sclerosing cholangitis (PSC) and colitis are chronic inflammatory disorders with malignant potential. Telomerase is an enzyme complex that lengthens telomeres and has enhanced expression in numerous malignancies. In this study, we evaluated the telomerase gene copy number, telomere length, cells in senescence, aneuploidy and additional parameters of telomere dysfunction from peripheral blood lymphocytes of patients.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* informed consent
* documented PSC and inflammatory bowel disease

Exclusion Criteria:

* under 18 years, above 80 y
* known active malignancy
* decompensated cirrhosis
* patients who cannot sign informed consent
```

## Arms

- **Healthy control**
- **IBD** — patients with inflammatory bowel disease, study group
- **PSC** — patients with primary sclerosing cholangitis, study group

## Primary Outcomes

- **Telomere length** _(time frame: 1.5 years)_

## Secondary Outcomes

- **number of cells with increased telomerase RNA component (TERC) expression** _(time frame: 1.5 years)_

## Locations (1)

- Meir Medical Center, Kfar Saba, Israel — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.meir medical center|kfar saba||israel` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02247622.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02247622*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*